Cargando…

High miR-30 Expression Associates with Improved Breast Cancer Patient Survival and Treatment Outcome

SIMPLE SUMMARY: Previous research on the miR-30 family and breast cancer patient survival and on miR-30-related chemosensitivity prompted us to design a comprehensive study on the role of the miR-30 family in general and on miR-30d in particular in breast cancer. We present a study consisting of a t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jamshidi, Maral, Fagerholm, Rainer, Muranen, Taru A., Kaur, Sippy, Potdar, Swapnil, Khan, Sofia, Netti, Eliisa, Mpindi, John-Patrick, Yadav, Bhagwan, Kiiski, Johanna I., Aittomäki, Kristiina, Heikkilä, Päivi, Saarela, Jani, Bützow, Ralf, Blomqvist, Carl, Nevanlinna, Heli
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8230388/ https://www.ncbi.nlm.nih.gov/pubmed/34200751 http://dx.doi.org/10.3390/cancers13122907

Ejemplares similares

MiR-34a Expression Has an Effect for Lower Risk of Metastasis and Associates with Expression Patterns Predicting Clinical Outcome in Breast Cancer
por: Peurala, Hanna, et al.
Publicado: (2011)

Breast tumors from CHEK2 1100delC-mutation carriers: genomic landscape and clinical implications
por: Muranen, Taru A, et al.
Publicado: (2011)

Recurrent moderate‐risk mutations in Finnish breast and ovarian cancer patients
por: Nurmi, Anna, et al.
Publicado: (2019)

Polygenic risk score is associated with increased disease risk in 52 Finnish breast cancer families
por: Muranen, Taru A., et al.
Publicado: (2016)

Relationship of patients' age to histopathological features of breast tumours in BRCA1 and BRCA2 and mutation-negative breast cancer families
por: Eerola, Hannaleena, et al.
Publicado: (2005)

Histopathological features of breast tumours in BRCA1, BRCA2 and mutation-negative breast cancer families
por: Eerola, Hannaleena, et al.
Publicado: (2005)

RAD51, XRCC3, and XRCC2 mutation screening in Finnish breast cancer families
por: Pelttari, Liisa M, et al.
Publicado: (2015)

Breeze: an integrated quality control and data analysis application for high-throughput drug screening
por: Potdar, Swapnil, et al.
Publicado: (2020)

Basal cytokeratins in breast tumours among BRCA1, BRCA2 and mutation-negative breast cancer families
por: Eerola, Hannaleena, et al.
Publicado: (2008)

Variants on the promoter region of PTEN affect breast cancer progression and patient survival
por: Heikkinen, Tuomas, et al.
Publicado: (2011)

FANCM c.5101C>T mutation associates with breast cancer survival and treatment outcome
por: Kiiski, Johanna I., et al.
Publicado: (2016)

Meta-analysis of three genome-wide association studies identifies two loci that predict survival and treatment outcome in breast cancer
por: Khan, Sofia, et al.
Publicado: (2017)

Impact of normalization methods on high-throughput screening data with high hit rates and drug testing with dose–response data
por: Mpindi, John-Patrick, et al.
Publicado: (2015)

NTHL1 is a recessive cancer susceptibility gene
por: Nurmi, Anna K., et al.
Publicado: (2023)

Comprehensive analysis of NuMA variation in breast cancer
por: Kilpivaara, Outi, et al.
Publicado: (2008)

Pathogenic Variant Spectrum in Breast Cancer Risk Genes in Finnish Patients
por: Nurmi, Anna K., et al.
Publicado: (2022)

FANCM mutation c.5791C>T is a risk factor for triple-negative breast cancer in the Finnish population
por: Kiiski, Johanna I., et al.
Publicado: (2017)

CHEK2 c.1100delC mutation is associated with an increased risk for male breast cancer in Finnish patient population
por: Hallamies, Sanna, et al.
Publicado: (2017)

Mast cells and eosinophils in invasive breast carcinoma
por: Amini, Rose-Marie, et al.
Publicado: (2007)

ATM variants and cancer risk in breast cancer patients from Southern Finland
por: Tommiska, Johanna, et al.
Publicado: (2006)

Genomic subtypes of breast cancer identified by array-comparative genomic hybridization display distinct molecular and clinical characteristics
por: Jönsson, Göran, et al.
Publicado: (2010)

High cyclin B1 expression is associated with poor survival in breast cancer
por: Aaltonen, K, et al.
Publicado: (2009)

Constitutional mosaicism for a BRCA2 mutation as a cause of early-onset breast cancer
por: Alhopuro, Pia, et al.
Publicado: (2020)

A search for modifying genetic factors in CHEK2:c.1100delC breast cancer patients
por: Wendt, Camilla, et al.
Publicado: (2021)

BACH1 Ser919Pro variant and breast cancer risk
por: Vahteristo, Pia, et al.
Publicado: (2006)

Breeze 2.0: an interactive web-tool for visual analysis and comparison of drug response data
por: Potdar, Swapnil, et al.
Publicado: (2023)

A Genome Wide Meta-Analysis Study for Identification of Common Variation Associated with Breast Cancer Prognosis
por: Rafiq, Sajjad, et al.
Publicado: (2014)

Cell–cell and cell–matrix interactions
por: Muranen, Taru
Publicado: (2013)

Genome-wide siRNA screening reveals several host receptors for the binding of human gut commensal Bifidobacterium bifidum
por: Kainulainen, Veera, et al.
Publicado: (2022)

Familial Breast Cancer in Southern Finland
por: Eerola, Hannaleena, et al.
Publicado: (1999)

Multi-Variant Pathway Association Analysis Reveals the Importance of Genetic Determinants of Estrogen Metabolism in Breast and Endometrial Cancer Susceptibility
por: Low, Yen Ling, et al.
Publicado: (2010)

Patient survival and tumor characteristics associated with CHEK2:p.I157T – findings from the Breast Cancer Association Consortium
por: Muranen, Taru A., et al.
Publicado: (2016)

Epigenetic analysis of sporadic and Lynch-associated ovarian cancers reveals histology-specific patterns of DNA methylation
por: Niskakoski, Anni, et al.
Publicado: (2015)

Markers associated with genomic instability, immunogenicity and immune therapy responsiveness in Metaplastic carcinoma of the breast: Expression of γH2AX, pRPA2, P53, PD-L1 and tumor infiltrating lymphocytes in 76 cases
por: Voutilainen, S., et al.
Publicado: (2022)

SNPs in lncRNA Regions and Breast Cancer Risk
por: Suvanto, Maija, et al.
Publicado: (2020)

Genetic variation of ESR1 and its co-activator PPARGC1B is synergistic in augmenting the risk of estrogen receptor-positive breast cancer
por: Li, Yuqing, et al.
Publicado: (2011)

Other short opinions/comments on moderate/low cancer genetic risk markers in medical practice and the article Genetic contribution to all cancers: the first demonstration using the model of breast cancers from Poland stratified by age at diagnosis and tumour pathology by Lubinski et al., Breast Cancer Res Treat 2008 Apr 15
por: Aittomäki, Kristiina
Publicado: (2008)

Ovarian Cancer Dissemination—A Cell Biologist’s Perspective
por: Farsinejad, Sadaf, et al.
Publicado: (2019)

TP53-based interaction analysis identifies cis-eQTL variants for TP53BP2, FBXO28, and FAM53A that associate with survival and treatment outcome in breast cancer
por: Fagerholm, Rainer, et al.
Publicado: (2017)

Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia
por: Malani, Disha, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_l72i0iu4vo1mpdnpb6lhesm8ht